Advertisement

Diabetes Therapy

, Volume 8, Issue 3, pp 623–624 | Cite as

Erratum to: Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study

  • Yujing Jin
  • Xiaowei Sun
  • Xichen Zhao
  • Tiehong ZhuEmail author
Open Access
Erratum
  • 657 Downloads

Erratum to: Diabetes Ther DOI 10.1007/s13300-017-0247-6

In the original publication, the data have been incorrectly updated within the results, discussion and Table 2. The correct data are given here.

The result in Table 2, presenting Hypoglycemic events at Week 12 currently reads: 2 (1.7).

This result should read: 2 (3.2).

The result in Table 2 presenting Hypoglycemic events at Week 36 reads: 3 (2.5).

This result should read: 3 (4.8).

The result in Table 2 presenting the Hypoglycemic events p value currently reads: 1.000.

This p value should read: 0.500.

The statement within the results section reads:

‘There was no significant difference in the incidence of hypoglycemia before and after treatment (1.7% vs. 2.5% χ 2 = 0.21; p = 1.000) (Table 2).’

This statement should read:

‘There was no significant difference in the incidence of hypoglycemia before and after treatment (3.2% vs. 4.8% χ 2 = 0.50; p = 0.500) (Table 2).’
Table 2

Changes in clinical parameters after 24 weeks’ basal-plus treatment

Parametersa

Week 12 (n = 63)

Week 36 (n = 63)

Mean difference (SD)

p value

HbA1c (%)

8.06 (0.71)

7.17 (0.54)

0.89 (0.56)*

<0.001

FBG (mmol/L)

6.23 (0.15)

6.20 (0.16)

0.03 (0.14)

0.118

PBG (mmol/L)

13.17 (1.72)

10.14 (2.20)

3.03 (1.53)*

<0.001

Basal insulin dosage (IU/kg/day)

0.36 (0.06)

0.35 (0.05)

0.01 (0.02)

0.073

Prandial insulin dosage (IU/kg/day)

0 (0)

0.14 (0.04)

0.14 (0.04)*

<0.001

Total insulin dosage (IU/kg/day)

0.36 (0.06)

0.50 (0.08)

0.14 (0.03)*

<0.001

Weight (kg)

73.19 (6.82)

73.28 (6.90)

0.08 (0.76)

0.379

Number of OADs used

2.71 (0.46)

2.12 (0.42)

0.60 (0.61)*

<0.001

OADs, n (%)

 α-glycosidase inhibitor

63 (100)

22 (34.9)

  

 Metformin

18 (28.6)

63 (100)

  

 Insulin secretagogue

59 (93.7)

10 (15.9)

  

Hypoglycemic events, n (%)

2 (3.2)

3 (4.8)

 

0.500

Other adverse events, n (%)

0 (0)

0 (0)

  

HbA1c glycated hemoglobin A1c, FBG fasting blood glucose, PBG postprandial blood glucose, OADs oral antidiabetic drugs

p < 0.01

aParameters are summarized as mean (SD) unless specified

The statement the discussion section reads: ‘In particular, the 40% of subjects in the present study who.’

This statement should read: ‘In particular, the 36.7% of subjects in the present study who.’

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright information

© The Author(s) 2017

Authors and Affiliations

  • Yujing Jin
    • 1
  • Xiaowei Sun
    • 1
  • Xichen Zhao
    • 1
  • Tiehong Zhu
    • 1
    Email author
  1. 1.Tianjin Medical University General HospitalTianjinChina

Personalised recommendations